Not in terms of management of R&D they're not. Couldn't be more different. Which is presumably why such a high proportion of Roche's pharma revenues is earned from DNA drugs. The acquisition will prove value destructive imo. And from a societal point of view will divert a lot of cash that payors shell out for high-priced biologics into less productive channels than currently is the case.
Roche – As used in #msg-35382402, the term merchant bank was not intended to be pejorative. I consider it an oddity that Roche’s most consequential decisions of the past few decades have been banking decisions, but this doesn’t make Roche a bad company.
Market Data 
Markets 
AI
